İşlek, ZeynepSağıroğlu, Ali AsramÜçışık, Mehmet HikmetKırbaş, Oğuz KaanDemirel, ErhanYurdasiper, AysuŞahin, FikrettinÖzer, Özgen2024-09-202024-09-202024İşlek, Z., Sağıroğlu, A. A., Üçışık, M. H., Kırbaş, O. K., Demirel, E., Yurdasiper, A. ... Özer, Ö. (2024). Experimental design and characterization of dual-antibody-conjugated all-trans retinoic acid-loaded lipid nanoparticles as a potential cancer therapy. Journal of Drug Delivery Science and Technology, 100. http://dx.doi.org/10.1016/j.jddst.2024.1059951773-22472588-8943http://dx.doi.org/10.1016/j.jddst.2024.105995https://hdl.handle.net/20.500.12511/12819Antibody-targeted immunotherapy has emerged in cancer therapies regarding checkpoint inhibition with monoclonal antibodies, such as anti-programmed death-ligand 1 (anti-PD-L1) either given alone or in combination. However, when given alone, it may fail to activate tumor-specific T cells. The combinational therapy of anti-PD-L1 with anti-4-1BB and all-trans retinoic acid (ATRA) has come into prominence due to disease heterogeneity, resulting in the synergistic effects associated with greater T-cell responses. This study introduces anti-PD-L1 and anti-4-1BB-conjugated ATRA-loaded solid lipid nanoparticles (SLNs), where the Design-Expert Program was applied for the optimization. Accordingly, antibody–conjugated ATRA-loaded SLNs had uniform dispersions with mean diameters of 179.6 ± 12.6 nm. The formulations achieved the encapsulation efficiency (EE %) of ATRA at 21.2 ± 1.4 %, regarding the three-dimensional response surface graph. The binding efficiency of anti-4-1BB and anti-PD-L1 antibodies were determined as 85.59 ± 7.3 % and 90.02 ± 5.4 %, respectively. The release profile of formulations indicated the biphasic release of ATRA (ie., 76 ± 4.4 %) from SLNs within 24 h via the Higuchi model. Particle size distributions of SLNs displayed a 7 % increase (i.e., 190.5 ± 7.63 nm) at 4 °C over 2 months. The experimental design of anti-PD-L1- and anti-4-1BB-conjugated- ATRA-loaded SLNs highlighted the promising strategy for the development of alternative formulations and the potential approach for further cancer therapies.eninfo:eu-repo/semantics/openAccessAll-Trans Retinoic Acid (ATRA)Anti-4-1BBAnti-Programmed Death-Ligand 1 (Anti-PD-L1)Antibody ConjugationSolid Lipid Nanoparticles (Slns)Surface ModificationArticle10010.1016/j.jddst.2024.105995Q10012906347000012-s2.0-85200490102Q1